PF-07265807 / Pfizer - LARVOL DELTA

Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=88 | Terminated | Sponsor: Pfizer | N=67 ➔ 88 | Trial completion date: Jun 2024 ➔ Nov 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jun 2024 ➔ Nov 2024; Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Colorectal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1

MERTK Inhibitor Associated Retinal Toxicity in a Human. (PubMed, Retin Cases Brief Rep) - "Patients taking MERTK inhibitors should be monitored by an ophthalmologist while on the drug. If toxicity develops, discussion of whether to continue the medication should take place between the patient, ophthalmologist, and oncologist, with consideration of the risks of vision loss versus benefits of taking the medication from a cancer perspective."

Journal • Esophageal Adenocarcinoma • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Ophthalmology • Solid Tumor • MERTK

Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=67 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Feb 2024 ➔ Jun 2024 | Trial primary completion date: Feb 2024 ➔ Jun 2024

Metastases • Trial completion date • Trial primary completion date • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1

Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=61 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=161 ➔ 61

Enrollment change • Enrollment closed • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1

Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma—A phase 1, open-label, pharmacokinetic, safety and tolerability study. (ASCO-GU 2023) - P1 | "The study started in late 2020 and is recruiting. Clinical trial information: NCT04458259."

Clinical • Metastases • P1 data • PK/PD data • Bladder Cancer • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • MERTK

Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors. (ASCO-GI 2023) - P1 | "The study began in Q4 2020 and is recruiting pts. Clinical trial information: NCT04458259."

Clinical • IO biomarker • Metastases • P1 data • PK/PD data • Tumor mutational burden • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • AXL • MERTK • TMB

Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=161 | Recruiting | Sponsor: Pfizer | Trial completion date: Feb 2024 ➔ Jun 2024 | Trial primary completion date: Feb 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1

[VIRTUAL] Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors. (ASCO 2021) - P1 | "Secondary endpoints: PK parameters of PF-07265807, objective response rate and duration of response . The study began enrolling pts in September 2020 and is still recruiting."

Clinical • P1 data • PK/PD data • Infectious Disease • Oncology • Solid Tumor • AXL • MERTK

Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - P1; N=155; Recruiting; Sponsor: Pfizer; N=37 ➔ 155; Trial completion date: Nov 2024 ➔ Dec 2023; Trial primary completion date: Nov 2024 ➔ Dec 2023

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1

[VIRTUAL] The potent and selective MERTK/AXL inhibitor PF-5807/ARRY-067 activates dendritic cells to cross-prime CD8+ T cells for anti-tumor activity (AACR 2021) - "Therefore, we find that PF-5807 activates DCs to cross-prime CD8+ T cells, which are necessary for tumor control and are likely responsible for the establishment of tumor-specific memory T cells. PF-5807 is currently in an ongoing Phase I clinical trial in patients with advanced or metastatic solid tumors, with the intent to explore combination with anti-PD-1/anti-PD-L1 antibodies."

Oncology • Solid Tumor • AXL • CD8 • IFNG • MERTK • TNFA • TYRO3

A Study of PF-07265807 In Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=37; Recruiting; Sponsor: Pfizer; Not yet recruiting ➔ Recruiting; Trial completion date: Mar 2023 ➔ Oct 2024; Trial primary completion date: Mar 2023 ➔ Oct 2024

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of PF-07265807 In Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=37; Not yet recruiting; Sponsor: Pfizer

Clinical • New P1 trial • Oncology • Solid Tumor